Skip to main content
OpenTrials
Suspended

NCT Number: NCT06870916

Supporting Informed Decision Making About Multi-cancer Early Detection Testing

To develop a new participant educational aid that can be used by participants to support informed decision-making about Multi-Cancer Early Detection (MCED) tests, which are new blood-based screening tests.

Why the study stopped: PI Request
Suspended

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

About this study

To develop a prototype participant educational aid that can be used by participants to support informed decision making about MCED testing. The aims of the pilot project include the following:

  • Conduct focus groups to explore preferences and concerns about MCED testing among adults of screening age.
  • Based on salient themes from focus group discussion, develop and administer surveys to explore preferences and concerns about MCED testing among adults of screening age.
  • Using findings from the focus groups and surveys, develop prototype patient educational aids about MCED testing following a user-centered design strategy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Recruitment and eligibility will be assessed by CCETR.CCETR staff will help distribute recruitment flyers, assess subject eligibility, and refer eligible subjects to the research team (Appendix B, C & I).

Exclusion criteria

  • History of cancer other than basil cell and squamous cell skin cancer, per self-report.

Treatment and study plan

Multi-cancer Early Detection

Other

Participants will participate in a focus group discussion asking about your knowledge, preferences, and concerns for MCEDs. During the focus group discussion, investigators will specifically talk about what the tests are and how to decide to get the test as well as their risks and benefits.

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Time frame: Through study completion; an average of 1 year.

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Mar 11, 2025
Registry last updated
Sep 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.